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Abstract: Recent reports suggested dendritic cells (DCs) to be important players in the pathogenesis of auto-
immune thyroid processes in humans. However, there are virtually no data addressing the influence of thyroid 
autoaggression-associated disturbances of thyrometabolic conditions on DCs biology. The aim of the study was 
to evaluate the influence of L-thyroxine supplementation on conventional and plasmacytoid peripheral blood 
DCs subtypes in patients with hypothyroidism due to Hashimoto’s thyroiditis (HT). Eighteen patients with newly 
diagnosed hypothyroidism due to HT were included into the study. All patients received L-thyroxine treatment 
with doses adjusted to reach euthyroidism. Peripheral blood DC subtypes structure and immunoregulatory 
phenotype were analyzed by flow cytometry in the same patient prospectively at two time points: (i) before 
and (ii) 3 months after beginning of L-thyroxine treatment (hypothyroidism vs. euthyroidism, respectively). 
Percentage of plasmacytoid DCs in peripheral blood mononuclear cells fraction was significantly decreased 
in the course of L-thyroxine treatment (0.27 ± 0.19 vs. 0.11 ± 0.08; p < 0.05), whereas we did not observe 
any changes in the number of conventional DCs. However, the phenotypic analysis showed a significant in-
crease of conventional DCs expressing CD86 and CD91 (64.25 ± 21.6% vs. 86.3 ± 11%; p < 0.05 and 30.75 ± 
± 11.66% vs. 44.5 ± 13.3%; p < 0.05; respectively) in euthyroid patients. Standard L-thyroxine supplementation 
in HT patients exerted significant immunoregulatory effects, associated with quantitative and phenotypic chan-
ges of peripheral blood DC subpopulations. (Folia Histochemica et Cytobiologica 2014, Vol. 52, No. 2, 138–143)
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Introduction
Dendritic cells (DCs) are considered to be the 
most efficient antigen presenting cells (APCs) and 
crucial regulators of primary and adaptive immune 
response. Depending on their subtype, maturation 
state and microenvironmental factors (including vast 
variety of cytokines, hormones and the interaction 
with other immune and non-immune cells) DCs are 
able to initiate, direct and control different kinds of 
inflammatory reaction, as well as to regulate immune 
tolerance mechanisms, both on central and peripheral 
levels [1, 2]. In humans there are two main subtypes 
of peripheral blood DCs — myeloid (or conventional) 
DCs (cDCs) and plasmacytoid DCs (pDCs), which dif-
fer substantially in phenotype and functional charac-
teristics [3]. Due to their powerful immunoregulatory 
properties, both populations of peripheral blood DCs 
have been implicated in pathogenesis of numerous 
human diseases of inflammatory origin, including 
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lupus erythematosus [4] and multiple sclerosis [5] 
and in mechanisms of immune escape in different 
malignancies [6]. Similarly, DCs are considered to 
play an important role already in the earliest phases 
of pathological events, leading to the autoimmune 
thyroid disease (AITD) in humans [7] and sponta-
neous autoimmune thyroid disease in BB rats [8], 
as well as in the immune response mounted against 
thyroid cancer [9, 10, reviewed extensively in 11]. 
Interestingly, results of animal studies suggested also 
that different populations of DCs exerted diverse and 
even contradictory effects on the development and 
clinical course of experimental autoimmune thyroidi-
tis (EAT) [12, 13]. In accordance with EAT data, the 
most recent findings suggest one of the specific regula-
tory DC subsets, pDCs to be a crucial cell population 
in thyroid autoaggression in humans [14]. In the light 
of the well-known interplay between hormonal and 
immune systems, it seems to be of great importance 
to characterize the influence of thyrometabolic con-
ditions on the inflammatory processes of AITD. In 
our previous work, performed on patients who were 
thyroidectomized because of differentiated thyroid 
cancer, we showed — for the first time — that thyroid 
hormones are important physiological regulators of 
naturally occurring human peripheral blood pDCs and 
cDCs, both in vivo and in vitro [15]. Additionally, such 
DC-associated regulatory effects were not observed 
in another group of thyroidectomized patients receiv-
ing systemically exogenous thyrotropin (TSH), which 
seems to further support the direct, independent of the 
TSH concentration fluctuations, influence of thyroid 
hormones on human peripheral blood DCs in vivo [16]. 
These findings, together with the analysis performed 
by Leskela and colleagues [14], arise a question about 
possible DC- dependent immunomodulatory effects of 
L-thyroxine (L-T4) supplementation in patients with 
hypothyroidism due to Hashimoto’s thyroiditis (HT). 
In our study, we assessed prospectively proportions 
and phenotype of peripheral blood conventional and 
plasmacytoid DCs at two consecutive time points in 
the same HT patient: (i) before beginning of L-T4 sup-
plementation, i.e. in a state of hypothyroidism, and (ii) 
after 3 months of sufficient L-T4 administration, i.e. in 
euthyroid state. Our analysis showed that L-T4 supple-
mentation in HT not only normalized thyrometabolic 
parameters, but also exerted significant quantitative 
and qualitative effects on both main peripheral blood 
DCs subtypes.
Material and methods
Patients. Venous blood samples, collected from patients 
with HT (n = 18) were submitted to analysis. The patients 
were recruited from the Department of Endocrinology 
and Metabolic Diseases, Polish Mother’s Memorial Hospi-
tal — Research Institute, Lodz, Poland. Only the patients 
with newly diagnosed hypothyroidism due to HT, with no 
history of L-T4 administration, were qualified for the study. 
Any concomitant immunological or metabolic disorders 
(i.e. diabetes mellitus) were regarded as exclusion criteria 
(for further patients characteristics see Table 1). All of 
the patients signed the informed consent, and the Ethics 
Committee of the Medical University of Lodz had approved 
the study protocol. Blood samples were collected between 
08.00 and 09.00 AM after an overnight fast. Venous blood 
was obtained by clean venipuncture (needle gauge 19), 
avoiding slow flowing draws and/or traumatic venipunctu-
res. The samples were collected from the same patient at 
two consecutive time points: (i) before commencement of 
L-T4 supplementation — hypothyroidism (mean value of 
TSH — 47.26 ± 20.3 mIU/l), and (ii) after 3 months of L-T4 
administration — euthyroidism (mean value of TSH — 1.4 ± 
± 1.2 mIU/l). 
Free triiodothyronine (FT3), free thyroxine (FT4) and 
TSH concentrations were measured by the immunoradio-
metric (IRMA) method with appropriate kits (BRAHMS, 
Berlin, Germany; normal values: TSH 0.3–4.0 mIU/l; FT3 
3.4–7.65 pmol/l; FT4 10–25 pmol/l). The concentrations of 
TgAb and TPOAb were measured by the electrochemilu-
minescence (ECLIA) method with appropriate kits (Roche 
Diagnostics Mannheim, Germany, normal values: TgAb 
< 115 IU/ml; TPOAb < 35 IU/ml) and equipment (Modular 
Analytics E170 — Roche Diagnostic).
Fluorescence-activated cell sorting (FACS) analysis. Pe-
ripheral blood mononuclear cells (PBMCs) were isolated 
from blood samples (obtained as described above) by cen-
trifugation on a discontinuous density gradient (Histopaque 
1077, SigmaAldrich, St. Louis, MO, USA). PBMCs were 
assessed by flow cytometry, using a FACSCalibur® cytometer 
and CELLQuest® software (BD Biosciences, San Jose, CA, 
Table 1. Clinical characteristics of study participants
Before L-T4  
treatment  
(n = 18)
After 3 months  
of L-T4 treatment 
(n = 18)
Age (years) 46.1 ± 13.17 46.1 ± 13.17
BMI [kg/m2] 25.6 ± 4.6 24.9 ± 4.4a
FT4 [pmol/ml] 6.5 ± 2.3 19.7 ± 3.6
a
FT3 [pg/ml] 1.1 ± 0.26 4.21 ± 1.05
a
TSH (mIU/l) 47.26 ± 20.3 1.4 ± 1.2a
TgAb [IU/ml] 910 ± 650 814 ± 760
TPOAb [IU/ml] 440 ± 270 320 ± 350a
a p < 0.05
140 Mariusz Stasiolek et al.
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2014
10.5603/FHC.2014.0013
www.fhc.viamedica.pl
USA). Peripheral blood DCs were recognized on the basis of 
surface expression of appropriate blood dendritic cell antigens 
(BDCAs) using fluorescein isothiocyanate (FITC) conjugated 
monoclonal antibodies (mAb) specific for BDCA1/CD1c 
and BDCA2/CD303. The conventional myeloid subset of 
DCs was defined as a population positive for BDCA1/CD1c 
(anti-CD1c-Ab, AD5-8E7, mouse IgG2a) and negative for 
CD19 (in order to exclude CD1c positive CD19+ B cells; phy-
coerythrin-cyanie dye (PE-Cy5) conjugated anti-CD19-Ab, 
HIB19, mouse IgG1). Plasmacytoid DCs were recognized 
as BDCA2/CD303 positive cells (anti-CD303-Ab, AC144, 
mouse IgG1). All DC populations were counterstained 
with phycoerythrin (PE) conjugated mAb: anti-HLA-DR 
(G46-6 (L243), mouse IgG2a), anti-CD11c (B-ly6, mouse 
IgG1), anti-CD40 (5C3, mouse IgG1), anti-CD80 (L307.4, 
mouse IgG1), anti-CD83 (HB15e, mouse IgG1), anti-CD86 
(2331(FUN-1), mouse IgG1), anti-CD91 (A2MR-a2, mouse 
IgG1), anti-CD123 (9F5, mouse IgG1). Monoclonal Ab 
specific for BDCA antigens, were purchased from Miltenyi 
Biotec (Bergisch Gladbach, Germany). All the other mAb and 
appropriate isotype controls were purchased from BD Bio-
sciences Pharmingen (San Jose, CA, USA). In each sample 
5 × 105 cells were stained (mAb concentration in each 
case as provided in “1 test” by manufacturer) and 
2 × 105 cells were collected in order to gain at least 
1 × 105 cells in PBMC gate. The results of FACS analysis 
were presented as percentage of positive cells in the whole 
PBMCs fraction. Figure 1 shows representative FACS analysis 
of plasmacytoid and conventional DCs. 
Statistical analysis. Statistical analyses were performed, 
using the STATGRAPHICS PLUS v. 5.0 software. Student’s 
t-test for paired samples was used to determine the signi-
ficance of differences in all the measured parameters with 
normal distribution, observed between patients before and 
during L-T4 therapy. For the data that were not normally 
distributed, nonparametric Wilcoxon’s rank test was used to 
determine the statistical significance of differences. P-value 
less than 0.05 was considered statistically significant.
Results
The quantitative flow cytometric analysis showed 
that the percentage of pDCs in the whole PBMCs 
fraction significantly decreased in the course of L-T4 
treatment (0.27 ± 0.19 vs. 0.11 ± 0.08; p < 0.05). 
Figure 1. Representative dot plots of FACS analysis. A. Distribution of cellular populations in forward and side scatter 
(FSC-SSC) picture, PBMCs were gated for further DC analysis (gate P1). B. BDCA1/CD1c+CD19- cDCs (quadrant 
Q4).C. BDCA2/CD303+CD123+ pDCs (quadrant Q2)
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Interestingly, we did not observe any quantitative ef-
fects of L-T4 treatment on cDCs population (Figure 2). 
However, the assessment of DC surface expression 
profile in the same patient before and during L-T4 
supplementation demonstrated a significant increase 
of cDCs expressing CD86 — one of the most import-
ant costimulatory molecules (64.25 ± 21.6% vs. 86.3 ± 
± 11%; p < 0.05). Also, the surface expression of 
CD91 was increased on cDCs in euthyroid patients, as 
compared to the hypothyroid state (30.75 ± 11.66% vs. 
44.5 ± 13.3%; p < 0.05) (Figure 3). To the contrary, 
the expression of both CD86 and CD91 on pDCs 
remained unchanged during our study. We did not 
observe any effects of L-T4 administration on the 
surface expression of HLA-DR and other investigated 
immunoregulatory markers (CD40, CD80, CD83, 
CD200), either in conventional or plasmacytoid DCs 
population (data not shown).
Discussion
The main finding of our prospective study is the 
modulatory effect of L-T4 supplementation on both 
plasmacytoid and conventional peripheral blood DCs 
subpopulations in HT patients. The involvement of 
DCs in the pathogenesis of various forms of autoim-
mune thyroid disease seems to be increasingly well 
documented [17]. However, there are still very little 
data based on human studies available. The analysis 
of transcriptomic profiles of thyroid tissue in different 
stages of Graves’ disease (GD) revealed progressive 
accumulation of changes in the expression of nume-
rous immune factors, among them — associated with 
pDCs [18]. On the cellular level, it has been shown that 
the decrease of regulatory T cells (Tregs) observed 
in peripheral blood of untreated GD patients was 
associated with elevated pDC/cDC proportion [19]. 
Moreover, in co-culture experiments the authors de-
monstrated that pDCs (but not cDCs) derived from 
untreated GD patients efficiently inhibited immu-
nosuppressive activity of Tregs [19]. Most recently, 
Leskela and colleagues [14] have shown decreased 
percentage of pDCs in PBMCs obtained both from 
patients with HT and GD, as well as disease- and 
disease-stage specific changes in immunoregulatory 
phenotype of pDCs. These peripheral blood findin-
gs were accompanied by increased accumulation of 
pDCs observed in thyroid tissue specimens from HT 
and GD patients [14]. Another research group has 
reported recently significant increase of thyroid infil-
trating pDC in untreated GD patients [7] and patients 
with HT. However, in HT these parameters did not 
depend on disease clinical stage [20]. 
Although the results published so far clearly point 
at pDCs as the population with crucial engagement 
in autoimmune mechanisms underlying various forms 
of human AITD associated with different hormonal 
parameters, none of the above mentioned studies 
encompassed a prospective analysis of the influence 
of thyrometabolic state on DCs in AITD patients. In 
our study, we analyzed ex vivo peripheral blood pDC 
and cDCs populations in the same HT patients before 
(in hypothyroid state) and 3 months after beginning 
of L-T4 supplementation (in euthyroid state). In 
concordance with the results presented by Leskela 
and colleagues [14], we observed low percentage 
Figure 3. The surface expression of immunomodulatory 
molecules CD86 and CD91 was analyzed in the same HT 
patient (n=18) before and 3 months after commencement 
of L-T4 treatment (i.e. hypothyroidism and euthyroidism, 
respectively). Bars represent mean values ± SD
Figure 2. The structure of peripheral blood DC subtypes 
(pDC and cDCs) was analyzed in the same HT patient 
(n=18) before and 3 months after commencement of L-T4 
treatment (hypothyroidism and euthyroidism, respectively). 
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of pDCs in our group of HT patients, however this 
parameter was further decreased in the course of 
L-T4 treatment. The percentage of cDCs remained 
unchanged after normalization of TSH and thyroid 
hormones levels. Still, in that population we observed 
an increased expression of CD86, whereas the expres-
sion of CD80 remained very low and unaffected by 
L-T4 supplementation. The molecules CD80 and 
CD86 belong to the most important members of B7 
family of costimulatory molecules and play a crucial 
role in the time- and stimulation-dependent regula-
tory loop of immune response. The CD86 molecule, 
present already on resting DCs, delivers the main 
costimulatory signal in the earliest stage of immune 
reaction. To the contrary, CD80 expressed first after 
previous proinflammatory stimulation is considered 
to exert its main action in later phases of immune 
response [21]. Thus, the increased expression of 
CD86 without change in CD80 status may rather 
represent a different basal functional characteristics 
of cDCs than a sign of undergoing proinflammatory 
stimulation. Also, the increased expression of CD91, 
molecule known to act as heat shock protein recep-
tor involved in cross presentation and T cell priming 
[22], may influence the basic ability and readiness of 
peripheral blood cDCs to react upon danger signal 
encounter. Taking together, these observations may 
suggest that thyrometabolic parameters affect in an 
unspecific manner immune parameters in the periphe-
ry, including modulation of various DC populations. 
However, in particular clinical situations, such as HT, 
this influence may differ, especially in the case of 
immune cell populations specifically engaged in the 
immunopathological events. This assumption could 
possibly explain why the effects exerted in vivo by L-T4 
on peripheral blood DCs in patients thyroidectomized 
because of differentiated thyroid cancer [15], differed 
from the results obtained in HT, most remarkably in 
the case of pDCs, cell population postulated as one of 
the most important elements of autoimmune process 
in this disease.
The observed modulatory effect of L-T4 on CD86 
expression on human peripheral blood cDCs seems 
to stay in line with the animal studies, which demon-
strated that the effects of thyroid hormones exerted 
on murine bone marrow-derived DCs in culture 
included modulation of CD86 expression and were 
associated with thyroid hormone receptor depen-
dent activation of NF-kB and Akt signaling [23, 24]. 
Moreover, these immunoregulatory effects of thyroid 
hormones could be inhibited by glucocorticosteroids 
in mechanism based on the down-regulation of the 
same transcriptional pathways [25].
DCs have been suggested in some experimental 
studies to correlate with the appearance of anti-thy-
roid antibodies [26]. However, we think that the 
decrease of anti-Tg Ab serum level observed in the 
course of L-T4 supplementation in our patients’ group 
may not be directly attributed to changes in peripheral 
blood DCs. In the light of the unclear etiopathological 
role of anti-Tg Abs this problem needs a large popu-
lation-based study to be resolved definitely.
We think that our results not only stay very well in 
concordance with the latest report regarding the role 
of DCs in AITD in humans [14] but also supplement 
significantly its findings. Taking into consideration 
the very high frequency of AITD [27] and common 
administration of drugs modifying thyroid hormones 
activity, we believe that the influence of thyrometa-
bolic conditions on immune system and — in parti-
cular — on DC function represents a very important 
issue of modern endocrinology and immunology and 
definitely deserves more attention both in clinical and 
laboratory medicine.
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